Telehealth GLP-1 prescriptions
A direct-to-consumer telehealth platform that connects patients with licensed clinicians to prescribe semaglutide and tirzepatide, the same active ingredients as Ozempic and Zepbound, for weight loss, delivered by mail from compounding pharmacies rather than sold as a supplement.
quality claims we could confirm ourselves, rather than repeat from the vendor's marketing.
Prescription-only semaglutide injectable, tirzepatide injectable, and a semaglutide oral tablet, dispensed after an online clinician review, not available without a prescription and not a supplement in any sense.
From $83.25/month (12-month plan); $224/month standard
From $83.25/month (12-month plan)
From $83.25/month (12-month plan)Everything Vaylen offers is a prescription medication, gated behind a licensed clinician's review of the patient's own submitted health information, not an over-the-counter supplement. Semaglutide and tirzepatide carry real, well-documented side effects and contraindications, and nothing on this page substitutes for that clinician's own evaluation. This entry describes what the service offers; it is not a recommendation to use it, and it is not medical advice.
Graded by whether we could confirm it ourselves or are only repeating what the vendor states. A vendor's honesty about its own testing is a different question from what a published trial shows, so this is a separate scale from the evidence grades on our guides.
This mirrors the outcome range reported in published semaglutide weight-loss trials generally, though it's presented on Vaylen's own site as an expected outcome for its specific patient population rather than a citation to a specific trial. We did not independently confirm Vaylen's own patient outcomes data.
Where the vendor states thisTirzepatide's dual-agonist mechanism and the roughly 20% average weight-loss figure are consistent with published tirzepatide trial data (the SURMOUNT program) at the population level. Whether Vaylen's own patients see comparable results specifically was not something we could verify independently.
Where the vendor states thisStated on the vendor's site as a service policy. We did not test this by submitting an application ourselves.
Where the vendor states thisSemaglutide and tirzepatide carry documented gastrointestinal side effects and specific contraindications, including for people with a personal or family history of certain thyroid cancers. A telehealth intake form is not the same depth of evaluation as an in-person physical with a doctor who knows your full history.
Vaylen's medications come from compounding pharmacies rather than the branded manufacturer, which is a distinct regulatory pathway with its own oversight, generally used when brand-name product is in shortage or for cost reasons. Worth understanding that distinction before assuming it's interchangeable with the branded product.
No. It's a telehealth platform that prescribes semaglutide and tirzepatide, the same active ingredients as Ozempic and Zepbound, following a licensed clinician's review. These are prescription drugs, not over-the-counter supplements.
Every fact above traces to one of these pages, published by the vendor itself and checked on September 13, 2026. Vendor policy pages change without notice, so if something here looks out of date, it probably is.
Compare against
Open pricing, public COAs, strict research-only gate
